Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WAI YUEN TONG MEDICINE HOLDINGS LIMITED

(位元堂藥業控股有限公司*)

(Incorporated in Bermuda with limited liability)

(Stock Code: 897)

INSIDE INFORMATION
PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO.

The Board would like to inform the shareholders and potential investors of the Company that based on the preliminary review of the draft unaudited consolidated management accounts of the Group for the Reporting Period and the information currently available to the Board, the Group is expected to record a change from a profit attributable to owners of the parent for the Corresponding Period of approximately HK$2.8 million to a loss attributable to owners of the parent of not more than HK$16.0 million for the Reporting Period.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Wai Yuen Tong Medicine Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**").

The board of directors of the Company (the "**Board**" or the "**Directors**") would like to inform the shareholders and potential investors of the Company that based on the preliminary review of the draft unaudited consolidated management accounts of the Group for the six months ended 30 September 2026 (the "**Reporting Period**") and the information currently available to the Board, the Group is expected to record a change from a profit attributable to owners of the parent for the six months ended 30 September 2025 (the "**Corresponding Period**") of approximately HK$2.8 million to a loss attributable to owners of the parent of not more than HK$16.0 million for the Reporting Period.

Such expected decrease in profit is mainly attributable to the combined effect of:

1. a significant increase in selling and distribution, and administrative expenses for the Reporting Period; and

2. a significant decrease in net fair value gains on investment properties for the Reporting Period.

These adverse factors were partially offset by an increase in revenue and gross profit for the Reporting Period, reflecting the Group's continued efforts in driving sales and improving its sales mix and gross profit margin, also partially offset by an increase in other income and gains, net and a decrease in finance costs during the Reporting Period.

As the Company is still in the course of finalising its results for the Reporting Period, the information contained in this announcement is solely based on the preliminary assessment by the Board after reviewing the draft unaudited consolidated management accounts of the Group for the Reporting Period which have yet to be finalised. Details of the performance of the Group for the Reporting Period will be disclosed in the interim results announcement of the Company, which is expected to be published by the end of November 2026 in accordance with the requirements under the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Wai Yuen Tong Medicine Holdings Limited
(位元堂藥業控股有限公司*)
Tang Ching Ho
Chairman and Executive Director

Hong Kong, 6 November 2026

As at the date of this announcement, the executive Directors are Mr. Tang Ching Ho, Ms. Tang Wai Man and Ms. Law Man Yee, Anita, and the independent non-executive Directors are Mr. Li Ka Fai, David, Professor Sit Wing Hang and Professor Chan Wing Kwong.

* *For identification purpose only*